Stock market today: S&P 500 falls as government shutdown, trade jitters persist
Investing.com - UBS raised its price target on Insmed (NASDAQ:INSM) to $194.00 from $140.00 on Tuesday, while maintaining a Buy rating on the biopharmaceutical company’s stock. The company, currently trading near its 52-week high of $166.44, has delivered an impressive 137.46% return year-to-date. According to InvestingPro analysis, the stock’s RSI suggests it’s in overbought territory.
The price target increase reflects UBS’s updated model that now includes additional indications for Insmed’s Brinsupri drug. With a market capitalization of $34.63 billion and strong revenue growth of 21.15%, the company maintains robust liquidity with a current ratio of 6.68. Despite Insmed’s stock already rising 136% year-to-date, UBS sees further upside potential.
UBS expects strong initial uptake for Brinsupri’s launch in non-cystic fibrosis bronchiectasis (NCFB), with first patient data coming in third-quarter earnings, scheduled for October 23, 2025. The firm models peak sales of approximately $6.5 billion for Brinsupri in NCFB, slightly above the consensus estimate of $6.3 billion. Discover more detailed financial insights and 13 additional ProTips with an InvestingPro subscription.
The investment bank also identified upcoming Phase 2b Brinsupri data in chronic rhinosinusitis without nasal polyps (CRSsNP) by year-end 2025 as a potential catalyst. UBS assigns a 40% probability of success for this indication, projecting worldwide unadjusted sales of approximately $3.1 billion.
UBS further noted that disclosure of TPIP’s Phase 3 trial design in idiopathic pulmonary fibrosis (IPF) could provide clarity on the treatment’s potential. The firm models a 60% probability of success for this indication with projected worldwide unadjusted sales of approximately $4.4 billion, an opportunity it believes is not currently reflected in consensus estimates.
In other recent news, Insmed has seen a series of positive developments that have caught the attention of several analysts. The company presented impressive Phase 2 data for its TPIP treatment for pulmonary arterial hypertension at the European Respiratory Society congress, leading TD Cowen to raise its price target from $154 to $193 while maintaining a Buy rating. Guggenheim also increased its price target to $172 from $125, following the company’s second-quarter 2025 results and the FDA approval of Brinsupri for non-cystic fibrosis bronchiectasis. Morgan Stanley adjusted its price target to $144 from $126, reflecting confidence in the growth potential of Insmed’s drug brensocatib.
Additionally, Truist Securities raised its price target to $139, highlighting the broad label approval of Brinsupri, which could represent a multi-billion dollar opportunity. William Blair initiated coverage on Insmed with an Outperform rating, citing the potential for significant valuation increases driven by the company’s key products, including Brinsupri, Arikayce, and TPIP. These developments suggest a positive outlook from analysts regarding Insmed’s future growth and market potential.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.